KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Invested Capital (2016 - 2025)

Historic Invested Capital for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $94.0 billion.

  • Pfizer's Invested Capital rose 61.67% to $94.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $94.0 billion, marking a year-over-year increase of 61.67%. This contributed to the annual value of $89.3 billion for FY2024, which is 93.0% down from last year.
  • Per Pfizer's latest filing, its Invested Capital stood at $94.0 billion for Q3 2025, which was up 61.67% from $89.9 billion recorded in Q2 2025.
  • Pfizer's 5-year Invested Capital high stood at $102.0 billion for Q2 2023, and its period low was $19.4 billion during Q4 2022.
  • Over the past 5 years, Pfizer's median Invested Capital value was $89.9 billion (recorded in 2025), while the average stood at $82.9 billion.
  • As far as peak fluctuations go, Pfizer's Invested Capital tumbled by 4752.33% in 2022, and later skyrocketed by 40491.55% in 2023.
  • Pfizer's Invested Capital (Quarter) stood at $78.3 billion in 2021, then increased by 23.5% to $96.7 billion in 2022, then dropped by 6.82% to $90.1 billion in 2023, then fell by 0.93% to $89.3 billion in 2024, then grew by 5.26% to $94.0 billion in 2025.
  • Its last three reported values are $94.0 billion in Q3 2025, $89.9 billion for Q2 2025, and $91.4 billion during Q1 2025.